SARS-CoV-2 Binding Peptide CDR3 Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting and treating COVID-19, such as PCR and antigen tests, face challenges including time-consuming processes, high costs, and difficulties in scaling up testing, while existing antibodies have limited cross-reactivity and potential risks like antibody-dependent enhancement.
Innovation Solution
Development of a SARS-CoV-2-binding peptide with specific amino acid sequences that can form multimers, allowing for rapid detection and potential therapeutic application by binding to the S1 subunit of the spike protein, enabling local administration and broad epitope recognition.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If PCR testing is used for SARS-CoV-2 detection, then measurement precision is improved, but loss of time and productivity deteriorate due to time-consuming processes and difficulty in scaling up
Solution Approach 1:
The patent extracts only the essential CDR3 amino acid sequence from the complete antibody structure to create a minimal peptide binding element. This extracted peptide retains SARS-CoV-2 binding capability while eliminating unnecessary structural components, enabling faster and simpler detection compared to full antibody-based PCR methods
Solution Approach 2:
The peptide is designed as a simple,低成本 binding element that can be rapidly synthesized and discarded after use. Unlike expensive antibodies requiring complex production and storage, the peptide offers a cost-effective, scalable solution for high-throughput testing without long-term stability requirements
2Reliability
If conventional antibodies are used for SARS-CoV-2 detection and treatment, then neutralizing capacity is achieved, but adaptability deteriorates due to limited cross-reactivity and antibody-dependent enhancement risks
Solution Approach 1:
The patent focuses exclusively on the CDR3 region, which is the most critical local component for antigen recognition and binding specificity. By optimizing only this local region rather than the entire antibody structure, the peptide achieves effective neutralization while maintaining flexibility for adapting to different coronavirus variants through simple sequence modifications
Solution Approach 2:
The invention changes the fundamental parameter from complete antibody sequences to specific CDR3 amino acid sequences. This parameter reduction allows for easier modification and optimization of binding affinity and cross-reactivity properties, enabling the same peptide framework to target multiple coronavirus strains by simply altering the CDR3 sequence
3Reliability
If complex antibody structures are used for SARS-CoV-2 binding, then neutralizing activity is achieved, but ease of manufacture deteriorates due to production complexity and cost
Solution Approach 1:
The patent segments the antibody molecule into its functional components and identifies CDR3 as the essential binding element. By using only this segmented portion rather than the complete antibody structure, the invention dramatically simplifies manufacturing while preserving neutralizing activity, as the CDR3 peptide can be synthesized independently without requiring complex antibody production systems
Solution Approach 2:
The CDR3 peptide is designed as a simple, inexpensive binding element that can be rapidly synthesized using standard peptide synthesis methods. This disposable-like approach eliminates the need for complex antibody production, purification, and storage infrastructure, making manufacturing significantly easier and more scalable
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The peptide enables rapid and effective detection of SARS-CoV-2 with high affinity and neutralizing capacity, potentially overcoming limitations of existing antibodies and testing methods by providing a cost-effective, scalable solution for COVID-19 diagnosis and treatment.
Implementation Method 1
a SARS-CoV-2-binding peptide comprising one or more structural domains comprising CDR3 consisting of an amino acid sequence of any of SEQ ID NOs: 1 to 9
Implementation Method 2
allowing for rapid detection and potential therapeutic application by binding to the S1 subunit of the spike protein
Data Source
AI summary
A peptide which binds to SARS-CoV-2 and its usage are provided. The peptide which binds to SARS-CoV-2 comprises one or more structural domain comprising CDR3 consisting of an amino acid sequence of any of SEQ ID NOs: 1 to 9 or an amino acid sequence obtained by substituting at least one amino acid in the amino acid sequence with another amino acid.